Avalo Therapeutics officer sells 2,655 shares

Avalo Therapeutics, Inc. Chief Strategy Officer Jennifer Riley reported a sale of 2,655 shares of common stock on August 11, 2026.

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. Chief Strategy Officer Jennifer Riley reported a sale of 2,655 shares of common stock on August 11, 2026. The shares were sold at a weighted average price of $19.5903 per share, in multiple transactions priced between $19.54 and $19.65. Following this sale, Riley directly holds 37,041 shares of Avalo Therapeutics common stock.

Insider Trade Summary

Net Seller: 2,655 shares

Net Sell 1 txn

Insider Riley Jennifer

Role Chief Strategy Officer

Sold 2,655 shs ($52K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	2,655	$19.5903	$52K

Holdings After Transaction: Common Stock — 37,041 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $19.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 2,655 shares Weighted average sale price: $19.5903 per share Price range of sales: $19.54–$19.65 per share +1 more

4 metrics

Shares sold 2,655 shares Common stock sale by Chief Strategy Officer on August 11, 2026

Weighted average sale price $19.5903 per share Average price for 2,655 common shares sold

Price range of sales $19.54–$19.65 per share Multiple transactions within this price range for the reported sale

Shares held after transaction 37,041 shares Direct ownership by Jennifer Riley following the sale

Key Terms

weighted average price, open market or private transaction, non-derivative

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"Sale in open market or private transaction"

non-derivative financial

"transaction_type": "non-derivative""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Avalo Therapeutics (AVTX) report for Jennifer Riley?

Avalo Therapeutics reported that Chief Strategy Officer Jennifer Riley sold 2,655 shares of common stock on August 11, 2026. After this transaction, she directly holds 37,041 shares of Avalo Therapeutics common stock.

How many Avalo Therapeutics (AVTX) shares did Jennifer Riley sell and at what price?

Jennifer Riley sold 2,655 shares of Avalo Therapeutics common stock at a weighted average price of $19.5903 per share. The sales occurred in multiple trades with prices ranging from $19.54 to $19.65 per share.

What are Jennifer Riley’s Avalo Therapeutics (AVTX) holdings after the reported sale?

After the reported sale, Jennifer Riley directly holds 37,041 shares of Avalo Therapeutics common stock. This post-transaction holding reflects her remaining direct ownership following the sale of 2,655 shares on August 11, 2026.

Was the Avalo Therapeutics (AVTX) insider sale by Jennifer Riley executed as multiple trades?

Yes. The filing states that the reported price is a weighted average and that the 2,655 shares were sold in multiple transactions. Those trades occurred at prices ranging from $19.54 to $19.65 per share, inclusive.

Does the Avalo Therapeutics (AVTX) filing describe the type of transaction for Jennifer Riley’s sale?

The transaction is coded as “S”, described as a sale in open market or private transaction. It involves non-derivative Avalo Therapeutics common stock and is categorized as a direct ownership transaction by Jennifer Riley.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 04:10 PM Accepted by SEC EDGAR 08/12/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Riley Jennifer

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Strategy Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2026		S		2,655	D	$19.5903(1)	37,041	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $19.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Christopher Sullivan, Attorney-in-Fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)